TMCnet News
DBV Technologies to Participate in Upcoming Investor ConferencesMontrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Sciences Conference – May 13, 2024 H.C. Wainwright BioConnect Conference – May 20, 2024 A live webcast of each presentation will be available on the Events page on the Investors section of the Company's website www.dbv-technologies.com. A replay will also be available for 90 days after each event. About DBV Technologies DBV Technologies is headquartered in Montrouge, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Media Contact
Attachment |